Anne-Sophie Gauchez
Research Subjects
Research Interests
Anne-Sophie Gauchez has a total of 319 co-authors. Here are the top co-authors by number of shared publications:
- Pierre-Jean Lamy
Clinique Beau Soleil, Montpellier, France
9 shared publications Daniel Fagret
UMR-S INSERM 1039 Bioclinical Radiopharmaceutical Unit, Grenoble, France; Nuclear Medicine Unit, Imaging Department, Grenoble University Hospital, Grenoble, France
6 shared publicationsMireille Mousseau
5 shared publicationsDominique Pasquier
4 shared publicationsNadia Ravanel
4 shared publicationsRaoul Payan
4 shared publications
Latest Publications
- Open Access
- 28 August 2023
- Published by Elsevier in Médecine Nucléaire
- Vol. 47 (5) , 226-232
Les marqueurs biologiques du cancer de la prostate : limites du PSA et place des nouveaux marqueurs
- 28 August 2023
- Published by Elsevier in Médecine Nucléaire
- Vol. 47 (5) , 226-232
Open AccessLes marqueurs biologiques du cancer de la prostate : limites du PSA et place des nouveaux marqueurs
- 12 August 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 422-426.e8
Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma
- 12 August 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (2) , 422-426.e8
Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma
- 7 April 2023
- Published by Elsevier in Médecine Nucléaire
- Vol. 47 (4) , 169-174
Screening for thyroid disease in pregnancy: Targeted or universal?
- 7 April 2023
- Published by Elsevier in Médecine Nucléaire
- Vol. 47 (4) , 169-174
Screening for thyroid disease in pregnancy: Targeted or universal?
- 15 May 2019
- Published by Elsevier in Médecine Nucléaire
- Vol. 43 (3) , 267-269
Le point sur les dosages de l’hormone gonadotrophine chorionique : lequel prescrire pour quelle prise en charge ?
- 15 May 2019
- Published by Elsevier in Médecine Nucléaire
- Vol. 43 (3) , 267-269
Le point sur les dosages de l’hormone gonadotrophine chorionique : lequel prescrire pour quelle prise en charge ?
- Open Access
- 12 March 2019
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 10 (1) , 1-12
Human mesenchymal stem cells improve rat islet functionality under cytokine stress with combined upregulation of heme oxygenase-1 and ferritin
Islets of Langerhans transplantation is a promising therapy for type 1 diabetes mellitus, but this technique is compromised by transplantation stresses including inflammation. In other tissues, co-transplantation with mesenchymal stem cells has been shown to reduce damage by improving anti-inflammatory and anti-oxidant defences. Therefore, we probed the protection afforded by bone marrow mesenchymal stem cells to islets under pro-inflammatory cytokine stress. In order to evaluate the cytoprotective potential of mesenchymal stem cells on rat islets, co-cultures were exposed to the interleukin-1, tumour necrosis factor α and interferon γ cocktail for 24 h. Islet viability and functionality tests were performed. Reactive oxygen species and malondialdehyde were measured. Expression of stress-inducible genes acting as anti-oxidants and detoxifiers, such as superoxide dismutases 1 and 2, NAD(P)H quinone oxidoreductase 1, heme oxygenase-1 and ferritin H, was compared to non-stressed cells, and the corresponding proteins were measured. Data were analysed by a two-way ANOVA followed by a Holm-Sidak post hoc analysis. Exposure of rat islets to cytokines induces a reduction in islet viability and functionality concomitant with an oxidative status shift with an increase of cytosolic ROS production. Mesenchymal stem cells did not significantly increase rat islet viability under exposure to cytokines but protected islets from the loss of insulin secretion. A drastic reduction of the antioxidant factors heme oxygenase-1 and ferritin H protein levels was observed in islets exposed to the cytokine cocktail with a prevention of this effect by the presence of mesenchymal stem cells. Our data evidenced that MSCs are able to preserve islet insulin secretion through a modulation of the oxidative imbalance mediated by heme and iron via heme oxygenase-1 and ferritin in a context of cytokine exposure.
- 12 March 2019
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 10 (1) , 1-12
Open AccessHuman mesenchymal stem cells improve rat islet functionality under cytokine stress with combined upregulation of heme oxygenase-1 and ferritin
Islets of Langerhans transplantation is a promising therapy for type 1 diabetes mellitus, but this technique is compromised by transplantation stresses including inflammation. In other tissues, co-transplantation with mesenchymal stem cells has been shown to reduce damage by improving anti-inflammatory and anti-oxidant defences. Therefore, we probed the protection afforded by bone marrow mesenchymal stem cells to islets under pro-inflammatory cytokine stress. In order to evaluate the cytoprotective potential of mesenchymal stem cells on rat islets, co-cultures were exposed to the interleukin-1, tumour necrosis factor α and interferon γ cocktail for 24 h. Islet viability and functionality tests were performed. Reactive oxygen species and malondialdehyde were measured. Expression of stress-inducible genes acting as anti-oxidants and detoxifiers, such as superoxide dismutases 1 and 2, NAD(P)H quinone oxidoreductase 1, heme oxygenase-1 and ferritin H, was compared to non-stressed cells, and the corresponding proteins were measured. Data were analysed by a two-way ANOVA followed by a Holm-Sidak post hoc analysis. Exposure of rat islets to cytokines induces a reduction in islet viability and functionality concomitant with an oxidative status shift with an increase of cytosolic ROS production. Mesenchymal stem cells did not significantly increase rat islet viability under exposure to cytokines but protected islets from the loss of insulin secretion. A drastic reduction of the antioxidant factors heme oxygenase-1 and ferritin H protein levels was observed in islets exposed to the cytokine cocktail with a prevention of this effect by the presence of mesenchymal stem cells. Our data evidenced that MSCs are able to preserve islet insulin secretion through a modulation of the oxidative imbalance mediated by heme and iron via heme oxygenase-1 and ferritin in a context of cytokine exposure.
- 1 December 2017
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 78 (6) , 488-489
Serum GH concentrations must now be expressed in mass units in France…as in the rest of the world
- 1 December 2017
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 78 (6) , 488-489
Serum GH concentrations must now be expressed in mass units in France…as in the rest of the world
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A17-A18
Apport des cellules souches mésenchymateuses pour la préservation de la fonctionnalité cellulaire béta dans la thérapie cellulaire du diabète de type 1
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A17-A18
Apport des cellules souches mésenchymateuses pour la préservation de la fonctionnalité cellulaire béta dans la thérapie cellulaire du diabète de type 1
- 1 January 2017
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 55 (11) , e259-e261
Evaluation of a human anti-mouse antibody rapid test for patients requiring radio-immunodiagnostic
- 1 January 2017
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 55 (11) , e259-e261
Evaluation of a human anti-mouse antibody rapid test for patients requiring radio-immunodiagnostic
- 1 November 2016
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 175 (5) , 411-419
Impact of sleep behavior on glycemic control in type 1 diabetes: the role of social jetlag
Background: Sleep behavior is changing toward shorter sleep duration and a later chronotype. It results in a sleep debt that is acquitted on work-free days, inducing a small but recurrent sleep misalignment each week, referred to as “social jetlag”. These sleep habits could affect health through misalignment with circadian rhythms.Objectives: The primary objective is to address the impact of sleep behavior on glycemic control, assessed by HbA1c, in patients with type 1 diabetes, independently of other lifestyle or sleep-related factors. The secondary objective is to address whether circadian phase affects glycemic control.Design: In total, 80 adult patients with type 1 diabetes (46% female) were included in a clinical cohort study.Methods: Sleep behavior was addressed objectively by a 7-day actimetry, lifestyle by questionnaires, sleep breathing disorders by nocturnal oximetry and circadian phase by dim light melatonin onset (DLMO).Results: Univariate analyses showed that chronotype (r = 0.23,P = 0.042) and social jetlag (r = 0.30,P = 0.008) were significantly associated with HbA1c. In multivariable analysis, social jetlag was the only sleep habit independently associated with HbA1c (β = 0.012 (0.006; 0.017),P < 0.001). HbA1c was lower in patients with a social jetlag below versus above the median (7.7% (7.1–8.7) and 8.7% (7.6–9.8),P = 0.011). DLMO was not associated with HbA1c. However, the later the DLMO, the worse the sleep efficiency (r = −0.41,P < 0.001) and fragmentation index (r = 0.35,P = 0.005).Conclusions: Social jetlag, a small but recurrent circadian misalignment, is associated with worse glycemic control in type 1 diabetes, whereas circadian phase is not. Further intervention studies should address the potential improvement of glycemic control by correcting social jetlag.
- 1 November 2016
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 175 (5) , 411-419
Impact of sleep behavior on glycemic control in type 1 diabetes: the role of social jetlag
Background: Sleep behavior is changing toward shorter sleep duration and a later chronotype. It results in a sleep debt that is acquitted on work-free days, inducing a small but recurrent sleep misalignment each week, referred to as “social jetlag”. These sleep habits could affect health through misalignment with circadian rhythms.Objectives: The primary objective is to address the impact of sleep behavior on glycemic control, assessed by HbA1c, in patients with type 1 diabetes, independently of other lifestyle or sleep-related factors. The secondary objective is to address whether circadian phase affects glycemic control.Design: In total, 80 adult patients with type 1 diabetes (46% female) were included in a clinical cohort study.Methods: Sleep behavior was addressed objectively by a 7-day actimetry, lifestyle by questionnaires, sleep breathing disorders by nocturnal oximetry and circadian phase by dim light melatonin onset (DLMO).Results: Univariate analyses showed that chronotype (r = 0.23,P = 0.042) and social jetlag (r = 0.30,P = 0.008) were significantly associated with HbA1c. In multivariable analysis, social jetlag was the only sleep habit independently associated with HbA1c (β = 0.012 (0.006; 0.017),P < 0.001). HbA1c was lower in patients with a social jetlag below versus above the median (7.7% (7.1–8.7) and 8.7% (7.6–9.8),P = 0.011). DLMO was not associated with HbA1c. However, the later the DLMO, the worse the sleep efficiency (r = −0.41,P < 0.001) and fragmentation index (r = 0.35,P = 0.005).Conclusions: Social jetlag, a small but recurrent circadian misalignment, is associated with worse glycemic control in type 1 diabetes, whereas circadian phase is not. Further intervention studies should address the potential improvement of glycemic control by correcting social jetlag.